摘要
目的探讨文拉法辛联合双歧三联活菌、马来酸曲美布汀对难治性肠易激综合征患者的治疗效果。方法本次研究对象来源于我院2015年7月~2016年7月收治的难治性肠易激综合征患者78例,随机分成两组各39例,对照组采用马来酸曲美布汀联合双歧三联活菌治疗,观察组基于对照组加用文拉法辛,比较两组临床疗效。结果观察组总有效率为94.9%,高于对照组71.8%(P<0.05);观察组症状频率指数、症状程度指数均明显低于对照组(P<0.05)。结论文拉法辛联合马来酸曲美布汀及双歧三联活菌治疗难治性IBS临床疗效优良,值得推广。
Objective The effects of venlafaxine combined with Jinshuangqi and trimebutine maleate in the treatment of refractory irritable bowel syndrome patients.Methods This study comes from our hospital in July 2015 -2016 year in July were refractory irritable bowel syndrome patients 78 cases, randomly divided into two groups, the control group（n=39） with trimebutine maleate combined with Jinshuangqi treatment,observation group（n=39） in the control group and venlafaxine on clinical efficacy between the two groups.Results The total effective rate of the observation group was 94.9%, which was higher than that of the control group（P〈0.05）.The symptom frequency index and symptom degree index of the observation group were significantly lower than those of the control group（P〈0.05）.Conclusion Venlafaxine combined with trimebutine maleate and bifidobacteria in the treatment of clinical efficacy in refractory IBS was excellent and worthy of promotion.
出处
《现代诊断与治疗》
CAS
2017年第17期3137-3138,共2页
Modern Diagnosis and Treatment
关键词
文拉法辛
马来酸曲美布汀
双歧三联活菌
难治性肠易激综合征
venlafaxine combined
trimebutine maleate
refractory irritable
bowel syndrome patients
refractory irritable
bowel syndrome
IBS
worthy
